Letters
Screening for prostate cancer
Authors’ reply to Kole
BMJ 2016; 354 doi: https://doi.org/10.1136/bmj.i3795 (Published 12 July 2016) Cite this as: BMJ 2016;354:i3795
- Ian E Haines, associate professor1 2,
- Richard J Ablin, professor3 4,
- George L Gabor Miklos, founder5
- 1Melbourne Oncology Group, Cabrini Medical Centre, Malvern 3144, Australia
- 2AMREP Department of Medicine, Monash University, Australia
- 3Department of Pathology, University of Arizona College of Medicine, Tucson, AZ, USA
- 4Arizona Cancer Center and BIO5 Institute, Tucson, AZ, USA
- 5Atomic Oncology, Newport, NSW 2106, Australia
- ian.haines{at}monash.edu
We thank Kole for his response to our article calling for release of data underpinning Public Health England’s (PHE) advice to GPs and men over 50 on PSA screening.1 2 He notes PHE’s emphasis on current uncertainty and why this data release is vital.
PHE’s first point, that “you are more likely to die of prostate cancer and/or to …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £184 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£50 / $60/ €56 (excludes VAT)
You can download a PDF version for your personal record.